- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04832828
Sensitivity and Specificity of the Roth Test in Patients With COVID-19 Positive
April 3, 2021 updated by: Raúl Ferrer-Peña, Universidad Autonoma de Madrid
The presence of the described silent hypoxia in subjects diagnosed with COVID19 highlights the need for valid tools to assess respiratory capacity.
The Roth test has been associated with acceptable sensitivity and specificity criteria in patients with previous respiratory pathology; however, its validity in this type of patient has not been proven.
Study Overview
Study Type
Observational
Enrollment (Actual)
114
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Madrid, Spain, 28053
- CS Entrevías
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
12 years to 99 years (Child, Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Non-Probability Sample
Study Population
Subjects aged 18 to 90 years were recruited by non-probabilistic convenience sampling in Primary Health Care Centres of the Primary Health Care Management of SERMAS and the Intensive Care Unit of the University Hospital of Gran Canaria Doctor Negrín of the Canary Health Service
Description
Inclusion Criteria:
- having been diagnosed as COVID-19 positive and with symptoms compatible with Sars-Cov-2 infection in the last 7 days prior to assessment,
- having an understanding of Spanish,
- and having no history of respiratory pathology prior to the current infection.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
COVID+ Group
Patients diagnosed with Covid19 positive in last 7 days
|
Subjets must count from 1 to 30 in their languages, and health professional will count seconds that last in take breath during the count.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Oxygen Saturation
Time Frame: 12 weeks
|
The pulseoximeter percentage value
|
12 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Roth´s test
Time Frame: 12 weeks
|
The level described in the test
|
12 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
June 1, 2020
Primary Completion (Actual)
November 28, 2020
Study Completion (Actual)
November 28, 2020
Study Registration Dates
First Submitted
March 31, 2021
First Submitted That Met QC Criteria
April 3, 2021
First Posted (Actual)
April 6, 2021
Study Record Updates
Last Update Posted (Actual)
April 6, 2021
Last Update Submitted That Met QC Criteria
April 3, 2021
Last Verified
April 1, 2021
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- PI-4321
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Covid19
-
Anavasi DiagnosticsNot yet recruiting
-
Ain Shams UniversityRecruiting
-
Israel Institute for Biological Research (IIBR)Completed
-
Colgate PalmoliveCompleted
-
Christian von BuchwaldCompleted
-
Luye Pharma Group Ltd.Shandong Boan Biotechnology Co., LtdActive, not recruiting
-
University of ZurichLabor Speiz; Swiss Armed Forces; Universitätsspital ZürichEnrolling by invitation
-
Alexandria UniversityCompleted
Clinical Trials on Roth´s Test
-
University of BaghdadRecruitingSkeletal and Dental CL I Malocclusion Moderate CrowdingIraq
-
Hospital St. Joseph, Marseille, FranceRecruiting
-
Memorial University of NewfoundlandRecruitingHIV Infections | HCV Infection | Syphilis InfectionCanada
-
Jordan University of Science and TechnologyCompleted
-
Hoffmann-La RocheCompleted
-
Ahram Canadian UniversityNot yet recruitingSmoking | Orofacial Dysfunction
-
University of CalgaryActive, not recruitingSyncope | Orthostatic Intolerance | Presyncope | FaintingCanada
-
Boehringer IngelheimCompleted
-
Sohag UniversityNot yet recruitingDermatologic Disorders With Heamatologic Malignancies PatientsEgypt
-
MicroPhage, Inc.CompletedSepsis | Bacteremia | Infection | Staphylococcal InfectionUnited States